INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $88,140 | -19.4% | 1,692,080 | -2.0% | 0.89% | -14.6% |
Q2 2023 | $109,372 | +15.2% | 1,727,287 | -1.5% | 1.04% | +12.9% |
Q1 2023 | $94,929 | +23.7% | 1,753,067 | +20.9% | 0.92% | +18.1% |
Q4 2022 | $76,754 | -99.9% | 1,450,382 | -1.1% | 0.78% | +3.3% |
Q3 2022 | $68,205,000 | +104.7% | 1,465,835 | +151.2% | 0.75% | +109.7% |
Q2 2022 | $33,312,000 | -0.9% | 583,593 | +6.2% | 0.36% | +19.7% |
Q1 2022 | $33,613,000 | +72.0% | 549,327 | +47.1% | 0.30% | +84.0% |
Q4 2021 | $19,539,000 | – | 373,320 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |